Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Idenix Pharmaceuticals, Inc. (IDIX - Snapshot Report) recently suffered a setback when the US Patent and Trademark Office Patent Trial and Appeal Board (USPTO) issued a verdict against it in the first phase of its patent dispute with Gilead Sciences Inc. (GILD - Analyst Report). The USPTO ruled that Gilead filed its application requesting a patent pertaining to hepatitis C virus therapies before Idenix Pharma. The news impacted Idenix Pharma’s shares negatively.

The USPTO ruling made Idenix Pharma the junior party and Gilead the senior party in the ongoing HCV patent related dispute. The second phase of the case is expected to begin in the second quarter of this year. In this determining phase of the HCV patent dispute, it would be decided which of the two companies was the first to invent. The company winning the second phase will clinch the case.

The silver lining for Idenix Pharma is that the junior party status assigned to it by the USPTO in the first phase will not determine the winner of the second phase and the entire case. Idenix Pharma stated in its press release that it does not expect the adverse USPTO ruling in the first phase of its HCV patent related dispute with Gilead to affect its pipeline development programs.

We note that the HCV market is highly lucrative. A sizeable population suffers from HCV the world over. However, the treated population is much lower. This leaves the field open for new treatments. Moreover, the current standard of care comes with several side effects, which make it difficult for patients to continue the treatment. Apart from Gilead and Idenix Pharma companies such as Johnson & Johnson (JNJ - Analyst Report) are also developing therapies to treat HCV.

Idenix Pharma carries a Zacks Rank #3 (Hold) in the short run. Gilead looks more attractive carrying a Zacks Rank #2 (Buy). Stocks like Cytokinetics, Inc. (CYTK - Snapshot Report) carry a Zacks Rank #1 (Strong Buy) in the pharma space. 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
VERTEX ENERG VTNR 8.25 +10.59%
MODINE MANUF MOD 17.12 +8.77%
CLAYTON WILL CWEI 140.03 +7.27%
E*TRADE FINA ETFC 22.67 +5.44%
KNIGHTSBRIDG VLCCF 13.22 +5.42%